These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26505529)

  • 1. Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects.
    Zha J; Badri PS; Ding B; Uchiyama N; Alves K; Rodrigues L; Redman R; Dutta S; Menon RM
    Clin Ther; 2015 Nov; 37(11):2560-71. PubMed ID: 26505529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
    Polepally AR; King JR; Ding B; Shuster DL; Dumas EO; Khatri A; Chiu YL; Podsadecki TJ; Menon RM
    Clin Pharmacokinet; 2016 Aug; 55(8):1003-14. PubMed ID: 26895022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.
    Polepally AR; Dutta S; Hu B; Podsadecki TJ; Awni WM; Menon RM
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):269-77. PubMed ID: 27310328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
    Menon RM; Badri PS; Wang T; Polepally AR; Zha J; Khatri A; Wang H; Hu B; Coakley EP; Podsadecki TJ; Awni WM; Dutta S
    J Hepatol; 2015 Jul; 63(1):20-9. PubMed ID: 25646891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
    Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
    Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
    Khatri A; Menon RM; Marbury TC; Lawitz EJ; Podsadecki TJ; Mullally VM; Ding B; Awni WM; Bernstein BM; Dutta S
    J Hepatol; 2015 Oct; 63(4):805-12. PubMed ID: 26070406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
    King JR; Dutta S; Cohen D; Podsadecki TJ; Ding B; Awni WM; Menon RM
    Antimicrob Agents Chemother; 2016 Feb; 60(2):855-61. PubMed ID: 26596948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.
    Gopalakrishnan S; Khatri A; Mensing S; Redman R; Menon R; Zha J
    Adv Ther; 2016 Apr; 33(4):670-83. PubMed ID: 27084721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
    Hézode C; Asselah T; Reddy KR; Hassanein T; Berenguer M; Fleischer-Stepniewska K; Marcellin P; Hall C; Schnell G; Pilot-Matias T; Mobashery N; Redman R; Vilchez RA; Pol S
    Lancet; 2015 Jun; 385(9986):2502-9. PubMed ID: 25837829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
    Chayama K; Notsumata K; Kurosaki M; Sato K; Rodrigues L; Setze C; Badri P; Pilot-Matias T; Vilchez RA; Kumada H
    Hepatology; 2015 May; 61(5):1523-32. PubMed ID: 25644279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
    King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients.
    Uojima H; Kobayashi S; Hidaka H; Kinbara T; Fujikawa T; Nakayama T; Yamanoue H; Kanemaru T; Hashimotoh T; Hyun Sung J; Kako M; Koizumi W
    Ann Hepatol; 2019; 18(1):109-115. PubMed ID: 31113578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.
    Gopalakrishnan SM; Polepally AR; Mensing S; Khatri A; Menon RM
    Clin Pharmacokinet; 2017 Jan; 56(1):1-10. PubMed ID: 27314261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.
    Badri PS; Dutta S; Wang H; Podsadecki TJ; Polepally AR; Khatri A; Zha J; Chiu YL; Awni WM; Menon RM
    Antimicrob Agents Chemother; 2016 Jan; 60(1):105-14. PubMed ID: 26459906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
    Khatri A; Trinh R; Zhao W; Podsadecki T; Menon R
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6244-51. PubMed ID: 27503645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
    Schnell G; Tripathi R; Krishnan P; Beyer J; Reisch T; Irvin M; Dekhtyar T; Setze C; Rodrigues L; Alves K; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
    J Med Virol; 2018 Jan; 90(1):109-119. PubMed ID: 28842997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
    Lalezari J; Sullivan JG; Varunok P; Galen E; Kowdley KV; Rustgi V; Aguilar H; Felizarta F; McGovern B; King M; Polepally AR; Cohen DE
    J Hepatol; 2015 Aug; 63(2):364-9. PubMed ID: 25839406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
    Khatri A; Dutta S; Marbury TC; Preston RA; Rodrigues L; Wang H; Awni WM; Menon RM
    Clin Pharmacokinet; 2017 Feb; 56(2):153-163. PubMed ID: 27389403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
    Sato K; Chayama K; Alves K; Toyoda H; Suzuki F; Kato K; Rodrigues L; Zhang X; Setze C; Pilot-Matias T; Burroughs M; Redman R; Kumada H
    Adv Ther; 2017 Jun; 34(6):1449-1465. PubMed ID: 28536999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
    Lin CW; Menon R; Liu W; Podsadecki T; Shulman N; DaSilva-Tillmann B; Awni W; Dutta S
    Clin Drug Investig; 2017 Jul; 37(7):647-657. PubMed ID: 28378135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.